Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michael S. Dahan"'
Autor:
Timothy S. Pardee, Akiva Mintz, Paul M. Bingham, Kiran Kumar Solingapuram Sai, Anirudh Sattiraju, Michael S. Dahan, Zuzana Zachar, Robert Shorr
Publikováno v:
Cancer Research. 78:4861-4861
CPI-613 is a novel inhibitor of mitochondrial metabolism that has recently shown promise in early stage clinical trials for pancreatic cancer, lymphoma, and leukemia. It is a lipoate analogue that selectively inhibits pyruvate dehydrogenase (PDH) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db68cac07467f4a229c888016aaa2dbd
https://doi.org/10.1158/1538-7445.am2018-4861
https://doi.org/10.1158/1538-7445.am2018-4861
Autor:
Kiran Kumar Solingapuram Sai, Paul M. Bingham, Boris Pasche, Zuzana Zachar, Anirudh Sattiraju, Frankis Almaguel, Stephanie Rideout, Minghui Wang, Moises Guardado, Michael S. Dahan, Shawn D. Stuart, Akiva Mintz
Publikováno v:
Cancer Research. 77:2867-2867
CPI-613 is a lipoate analogue that has been shown to inhibit the pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KGDH) complexes selectively in tumor cells (reviewed in Exp.Rev.Clin.Pharma. 7, 837). These two enzymes control the v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::046c85b6d65c06ba307614ea746ef549
https://doi.org/10.1158/1538-7445.am2017-2867
https://doi.org/10.1158/1538-7445.am2017-2867
Publikováno v:
Molecular Cancer Research. 14:A61-A61
We will describe recent progress in understanding the role of cancer metabolic remodeling in determining the response of tumors and tumor cells to a novel, first-in-class clinical agent class selectively targeting cancer cell mitochondrial metabolism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4e1609aafc527bdc923048065ad4f84
https://doi.org/10.1158/1557-3125.metca15-a61
https://doi.org/10.1158/1557-3125.metca15-a61